296 related articles for article (PubMed ID: 30926356)
1. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
2. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
5. Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Lim YJ; Chang JH; Kim HJ; Keam B; Kim TM; Kim DW; Paeng JC; Kang KW; Chung JK; Jeon YK; Chung DH; Wu HG
Clin Lung Cancer; 2017 May; 18(3):e169-e178. PubMed ID: 28131636
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
8. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
[TBL] [Abstract][Full Text] [Related]
9. [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].
Li F; Bai H; Li X; Wu M; Yu R; Shi A; Yin L; Wang J; Zhu G
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):715-8. PubMed ID: 21924037
[TBL] [Abstract][Full Text] [Related]
10. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Chaft JE; Dagogo-Jack I; Santini FC; Eng J; Yeap BY; Izar B; Chin E; Jones DR; Kris MG; Shaw AT; Gainor JF
Lung Cancer; 2018 Aug; 122():67-71. PubMed ID: 30032847
[TBL] [Abstract][Full Text] [Related]
12. EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2023 Apr; 55(2):498-505. PubMed ID: 36228655
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.
He CH; Shih JF; Lai SL; Chen YM
J Chin Med Assoc; 2020 May; 83(5):461-465. PubMed ID: 32221155
[TBL] [Abstract][Full Text] [Related]
14. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
[TBL] [Abstract][Full Text] [Related]
15. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
Djambazov SN; Vekov TY; Mekov EV; Slavchev GS; Petkov RE; Kostadinov DT; Konteva LT
Folia Med (Plovdiv); 2018 Sep; 60(3):397-401. PubMed ID: 30355843
[TBL] [Abstract][Full Text] [Related]
16. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
18. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
19. EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Park SE; Noh JM; Kim YJ; Lee HS; Cho JH; Lim SW; Ahn YC; Pyo H; Choi YL; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):493-501. PubMed ID: 29914238
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]